Document:

<PAGE>

                                                                    EXHIBIT 10.5

                        ASSIGNMENT AND ROYALTY AGREEMENT
                        --------------------------------

     This Agreement is made and entered this 12th day of Dec 1994, by and
between Diamedix Corporation, a Florida corporation having its principal place
of business located at 2140 North Miami Avenue, Miami, Florida 33127
(hereinafter referred to as "Diamedix") and Mario Cossi, a citizen of Italy
residing at Via Stesicoro, 148-Roma Riccardo Cossi, a citizen of ITALY residing
at Via Stesicoro, 148-Roma (hereinafter individually referred to as an
"Inventor" and collectively as the "Inventors").

                                   WITNESSETH:
                                   -----------

     WHEREAS, the Inventors declare and represent that they are co-inventors of
an innovative line of automated instrumentation for "ELISA" testing featuring
one or more of the following functions: (i) bar code sample identification; (ii)
predilution of sample; (iii) dispensing of sample into microwells; (iv)
dispensing of the various reagents in a desired sequence; (v) washing of the
microplate; (vi) automatic thermostat control capability; (vii) plate reader by
spectrophotometric technique or other technique utilized to read analytical
results; and (viii) print-out of results, and a specially designed software to
allow the performance of one or more of the foregoing functions (hereinafter
collectively referred to as the "Invention");

     WHEREAS, the Inventors have produced a prototype of one of the aforesaid
instruments which is currently being tested, which instrument is described on
Exhibit A attached hereto and made a part hereof and is currently designated as
"EASY EIA 1 " (hereinafter referred to as "Instrument #1 ");

     WHEREAS, a second instrument currently designated as "EASY EIA 2" and
described on Exhibit B attached hereto and made a part hereof (hereinafter
referred to as "Instrument #2") is currently under study by the Inventors and it
is expected that a prototype of such instrument will be completed within 9
months from the date of this Agreement;

     WHEREAS, Diamedix desires to acquire the entire right, title and interest
in and to the Invention, including, without limitation, Instrument #1 and
Instrument #2 and any other instruments and software that the Inventors may
develop with respect to the Invention (collectively, the "Instruments"), and
applications for patent protection of the Invention in the United States and in
foreign countries throughout the world, and in and to any patents which may be
obtained upon said applications or for said Invention therein contained in the
United States of America and all foreign countries, and in and to any reissues
or extension of any patents which may be granted for said Invention, and in and
to any improvements, additions to, or modifications of said Invention which the
Inventors may acquire by invention or otherwise;

     WHEREAS, in consideration of the foregoing assignment Diamedix has agreed
to pay the Inventors a royalty payment as more specifically set forth in this
Agreement;

     NOW THEREFORE, for and in consideration of the mutual covenants and
agreements set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto
hereby agree as follows:
<PAGE>

1.   Assignment.
     ----------

     Each of the Inventors does hereby sell, assign and transfer unto Diamedix,
its successors and assigns, the entire exclusive right, title and interest
throughout the world in and to the Invention, the Instruments, any and all
technology, know-how, improvements, formulas, software, trade secrets,
compositions, manuals, procedures, practices, techniques, methods and processes
and other proprietary or confidential information used in or relating to the
Invention, including related procedures, files and manuals and all source and
object codes and documentation related thereto (collectively referred to as
"Technical Information"), and in and to applications for patent protection of
the Invention in the United States and in foreign countries throughout the
world, and any continuations, continuations-in-part, additions, substitutions,
renewals or divisions thereof, and in and to any patents which may be obtained
thereon or therefor in the United States of America and in all foreign
countries, and in and to any reissues or extensions of any patents which may be
granted for said Invention, and in and to any improvements, additions to, or
modifications of said Invention which the Inventors may acquire by invention or
otherwise, the same to be held and enjoyed by Diamedix for its own use and
benefit, and for the use and benefit of its successors and assigns, as fully and
as entirely as the same might be held by the Inventors had this assignment, sale
and. transfer not been made.

2.   Representations and Warranties.
     -------------------------------

     The Inventors hereby, jointly and severally, represent and warrant that
they are the sole and absolute owners of the Invention and have the full right
to convey the entire interest herein assigned, that they have not executed and
will not execute any instrument inconsistent with the rights granted herein, and
that to the best of their knowledge, the manufacture, use or sale of the
Instruments, or any other products which embody or the manufacture or use of
which employ the Invention, by Diamedix or its successors or assigns will not
infringe any of the patent rights or other proprietary rights of any third
party. Each of the Inventors hereby binds himself and his heirs, executors,
administrators and legal representatives to execute and deliver any and all
papers and instruments and to do any and all acts which may be necessary or
required by Diamedix, in order to carry into full force and effect this sale,
assignment and transfer and to perfect the title to said Invention, Instruments,
Technical Information, improvements, patent applications, and patents in
Diamedix, its successors and assigns. Each of the Inventors further represents
and warrants that he hereby binds himself and his heirs, executors,
administrators and legal representatives to communicate to Diamedix, its
successors and assigns, at any time upon any of their request, any facts
relating to said Invention, Instruments, Technical Information, improvements,
patent applications, and patents and the history thereof known to him or to his
heirs, executors, administrators and legal representatives. In addition, the
Inventors hereby agree that if any new development or improvement relating to
the Invention or Technical Information shall become known to either of the
Inventors, they shall promptly disclose such new development or improvement and
furnish all relevant information to Diamedix.

                                       2
<PAGE>

3.   Royalty Payments.
     ----------------

     3.1 In consideration of the sale, transfer and assignment to Diamedix
hereunder, Diamedix shall pay collectively to the Inventors the following
royalty:

               (i) $1,000 for each Instrument # 1 produced by Diamedix or any of
its affiliates, provided, however, that the foregoing payment shall not be
applicable for the first ten Instruments #1 produced; and

               (ii) $1,500 for each Instrument #2 produced by Diamedix or any of
its affiliates, provided, however, that the foregoing payment shall not be
applicable f9Lthe first ten instruments #2 produced.

     3.2 Royalties payable hereunder shall not be due by Diamedix, with above
until 18 months after the production of the 15th Instrument #1, and with respect
to Section 3.1 (ii) above, until 18 months after the production of the 11th
Instrument #2. Thereafter, royalty payments shall be due and payable on a
quarterly basis, within 30 days after the end of each calendar quarter, based
upon the amount of Instruments #1 and #2 produced during the quarter just ended
(except for the first payment which shall also include payment of accrued but
unpaid royalties). Subject to the foregoing accrual period, the foregoing
royalty payments shall be payable for a period of five years from the date of
the production of the 11th Instrument # 1, with respect to payments under
Section 3.1 (i) above, and for a period of five years from the date of the
production of the 11th Instrument #2, with respect to payments under Section 3.1
(ii) above.

     3.3 Diamedix, at its sole option, shall have the right to terminate its
ongoing royalty obligations under Section 3.1 above by sending the Inventors
written notice of its intention to do so and by paying the Inventors the
following lump sum payment:

          a. In the event Diamedix chooses to terminate its ongoing royalty
obligations between July 1, 1996 and December 31, 1996, Diamedix shall pay
collectively to the Inventors a lump sum payment equal to: (i) $4,000 for each
Instrument #1 produced by Diamedix or any of its affiliates beginning with the
11th Instrument #1 produced and including all Instruments #1 produced by such
parties thereafter until the date of termination, and (ii) $6,000 for each
Instrument #2 produced by Diamedix or any of its affiliates beginning with the
11th Instrument #2 produced and including all Instruments #2 produced by such
parties thereafter until the date of termination;

          b. In the event Diamedix chooses terminate its ongoing royalty
obligations on or after January 1, 1997, Diamedix shall pay collectively to the
Inventors a lump sum payment equal to: (i) $3,000 for each Instrument #1
produced by Diamedix or any of its affiliates beginning with the 15th Instrument
#1 produced and including all Instruments #1 produced by such parties thereafter
until the date of termination, and (ii) $4,500 for each Instrument #2 produced
by Diamedix or any of its affiliates beginning with the 11th Instrument #2
produced and including all Instruments #2 produced by such parties thereafter
until the date of termination.

                                       3
<PAGE>

          c. Any and all amounts paid by Diamedix to the Inventors pursuant to
Section 3.1 hereof shall be credited towards the lump sum payment provided for
under this Section 3.3.

     3.4 Royalty payments shall be made hereunder to AXA DIAGNOSTICI SRL, at the
following address Via Varrone 45, 00040 Pomezia, Rome or such other place as the
Inventors and AXA DIAGNOSTICI SRL jointly may reasonably designate, in United
States dollars. Diamedix shall deduct any withholding or similar tax required to
be remitted by it from payments due and payable hereunder and shall provide the
Inventors with proof of payment therof upon request.

     3.5 The obligation of Diamedix to pay royalties and other amounts under
Section 3.1 or 3.3 hereof, shall terminate in the event of a breach by either of
the Inventors under that certain Consulting Agreement entered into
simultaneously hereto by and between each of the Inventors and Diamedix.

     3.6 Following Diamedix's final royalty payment due hereunder (whether under
Section 3.1, 3.3 or 3.5 hereof), all rights granted to Diamedix herein shall
continue but shall become fully paid-up.

     3.7 As additional consideration for the sale, transfer and assignment to
Diamedix hereunder, Diamedix shall reimburse the Inventors for their expenses
incurred to date in connection with the development of the Invention up to a
maximum aggregate amount of $10,000, upon submission by the Inventors to
Diamedix of proper supporting documentation.

4.   The Inventors' Obligation to Cooperate to Obtain Patents.
     --------------------------------------------------------

        Each of the Inventors hereby covenants and agrees that Diamedix, its
successors and assigns, may apply for, prosecute, advance and cause the issuance
or grant of the patents and claim the benefits of the International Conventions,
and that if reissues of said patents or disclaimers relating thereto, or
divisions, continuations, or refilings of any of said patents shall hereafter be
desired by Diamedix, its successors or assigns, the Inventors will, at any time,
when reasonably called upon to do so by Diamedix, its successors or assigns,
sign all lawful papers, make all rightful oaths, execute and deliver all such
disclaimers and all divisional, continuation and reissue applications so
desired, and do all lawful acts requisite for the application for such reissues
and the procuring thereof and for the filing of such disclaimers and such
divisional and continuation applications, and generally do everything possible
to aid Diamedix, its successors and assigns, to obtain and enforce proper patent
protection for said Invention in all countries of the world, without further
compensation or other renumeration but at the expense of Diamedix, its
successors and assigns. The Inventors shall maintain as confidential all
information relating to any application for such patent rights, including,
without limitation, information relating to the existence, content, or status of
any such application. Each of the Inventors hereby authorizes and requests the
Commissioner of Patents and Trademarks of the United States and any official of
any country foreign to the United States whose duty it is to issue any and all
patents which may be granted for said Invention or improvements, to issue all
such patents for said Invention and improvements to Diamedix as the assignee of
the Inventors' entire right, title and interest therein.

                                       4
<PAGE>

5.   Patent Infringement.
     -------------------

     In the event that any suit, action or other proceeding shall be brought or
threatened against Diamedix, its affiliates, successors or assigns involving any
claim of infringement relating to the manufacture, use or sale of the
Instruments as a result of or relating to the use or practice of the Invention,
and as a result of such suit, action or other proceeding, Diamedix, its
affiliates, successors or assigns is obligated to pay a royalty or specified
damages to a third party, Diamedix' royalty payments to the Inventors hereunder
shall be reduced in an equal amount. In addition, in the event that any of the
Instruments sold by Diamedix, its affiliates, successors or assigns to a third
party in a country wherein the making, using or selling of such Instrument is an
infringement of one or more claims of one or more valid unexpired patents owned
by a third party, and Diamedix, its affiliates, successors or assigns acquire a
license from such third party in order to make, have made, use or sell such
Instrument, Diamedix shall have the right to reduce the royalties payable to the
Inventors hereunder by an amount equal to that paid under such license.

6.   Production of instrument #1 and #2.
     ----------------------------------

     The Inventors hereby represent and warrant that the first run of five
Instruments #1 will be completed within 3 months from the date of this
Agreement. The Inventors further represent that the prototype for Instrument #2
will be completed within 9 months from the date of this Agreement and the first
run of five Instruments #2 will be completed with 12 months from the date of
this Agreement. In the event the foregoing time table is not met, Diamedix will
have the right to terminate this Agreement without any obligation or liability
whatsoever.

7.   Definition.
     ----------

     For the purpose of this Agreement, "affiliate" of a party shall mean any
corporation or business entity controlling, controlled by or under common
control with such party. "Control" shall mean the direct or indirect ownership
of at least fifty percent (50%) of the outstanding voting or equity interest in
such corporation or other business entity.

8.   Governing Law and Interpretation.
     --------------------------------

     This Agreement shall be governed by and interpreted in accordance with the
laws of the State of Florida, U.S.A. both substantive and remedial. In the event
that this Agreement is translated into a language other than English, the
English version of this Agreement shall control its interpretation. The parties
agree that a court of competent jurisdiction located in Dade County, Florida,
U.S.A. shall be the sole and exclusive venue for resolution of any disputes or
disagreements among the parties relating to this Agreement or the transactions
contemplated hereby or otherwise arising hereunder or with respect to any breach
of the terms and provisions hereof.

9.   Captions.
     --------

     The captions of this Agreement are solely for the convenience of reference
and shall not affect its interpretation.

                                       5
<PAGE>

10.  Entire Agreement.
     ----------------

     This Agreement represents the entire understanding as of the effective date
hereof between the parties with respect to the subject matter hereof, and
supersedes all prior agreements, negotiations, understandings, representations,
statements and writings between the parties relating thereto. No modification,
alteration, waiver or change in any of the terms of this Agreement shall be
valid or binding upon the parties hereto unless made in writing and duly
executed by each of the parties hereto.

11.  Counterparts.
     ------------

     This Agreement may be executed in one or more counterparts, each of which
shall be considered to be an original.

12.  Severability.
     ------------

     If any provision of this Agreement or portion thereof, or the application
thereof to any person or circumstances or in any country, shall be held to any
extent invalid or unenforceable, the remainder of this Agreement (or of such
provision) and the application thereof to other persons or circumstances or in
other countries shall not be affected thereby.

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the day
and year first written above.

DIAMEDIX CORPORATION                                    INVENTORS:

By: /s/ Giorgio D'Urso                                  By: /s/ Mario Cossi
    ------------------                                      --------------------
        Giorgio D'Urso                                          Mario Cossi

                                                        By: /s/ Riccardo Cossi
                                                            --------------------
                                                                Riccardo Cossi

STATE OF        )
                :ss.
COUNTY OF       )

     On this       day of          , 1994, before me personally came Mario Cossi
            ------        --------
and Riccardo Cossi, to me known and known to me to be the individuals named in
and who executed the foregoing instrument, and they each duly acknowledged to me
that they executed the same.

(Seal) WITNESS: /s/ Giovanni Furino                  WITNESS: /s/Elisa Accone
                -------------------                           ------------------
                    Giovanni Furino                              Elisa Accone

                                       6
<PAGE>

                                   EXHIBIT A
                                   ---------

Instrument # 1 "EASY EIA 1" with the following minimum characteristics:
                ----------

     a)   Bar code sample identification

     b)   Capability to run 4 microplates simultaneously

     c)   Predilution of the sample by means of a single probe

     d)   Ability to dispense sample in microplate

     e)   Ability to dispense reagents

     f)   Ability to wash 8 wells simultaneously

     g)   Ability to bring the 4 microplates to working temperature
          independently one from the other

     h)   Built-in computer to run the instrument and option for built-in
          keyboard

     i)   Software featuring.

          i.   Random access

          ii.  Ability to perform from one (1) to twelve (12) different analytes
               simultaneously on the same microplate

          iii  Ability to perform from one (1) to twelve (12) different analytes
               simultaneously on four (4) microplates

          iv.  Interface with computer and reader to produce patient profiles

          v.   Interface of instrument with two most widely used main frame
               computers in the laboratory

          vi.  Control system to check the instrument's main functions

          vii. Ability to provide historical data base

          viii. Localizable software

                                       7
<PAGE>

                                   EXHIBIT -
                                   ---------

Instrument #2 "EASY EIA 2" with the following minimum characteristics:
               ----------

     a)   Bar code sample identification

     b)   Capability to run 6 or more microplates simultaneously

     c}   Predilution of the sample

     d)   Ability to dispense sample by means of a needle with the option of
          disposable tips to avoid sample to sample carryover

     e)   Ability to dispense reagents

     f)   Ability to wash the microplate by means of an eight-tip manifold

     g)   Independent thermostat for each of the six microplates

     h)   Automatic mechanism to move plates to the reader incorporated in the
          instrument

     i)   Automatic printout of results

     j)   Built-in computer to operate the instrument

     k)   Software featuring:

          i.   Random access

          ii.  Ability to perform from one (1) to twelve (12) different analytes
               simultaneously on the same microplate;

          iii. Ability to perform from one (1) to twelve (12) different analytes
               simultaneously on the six (6) microplates;

          iv.  Interface between computer and reader to produce patient profiles

          v.   Interface between computer, reader and two of the most widely
               used main frame computers in the laboratory.

          vi   Control system to check the instrument's main functions

          vii. Ability to provide historical data base

          viii. Localizable software.

                                       8
<PAGE>

                  AMENDMENT TO ASSIGNMENT AND ROYALTY AGREEMENT

     This Amendment to Assignment and Royalty Agreement (the "Amendment"), dated
as of the lst day of February, 1997 by and between Diamedix Corporation, a
Florida corporation having its principal place of business located at 2140 North
Miami Avenue, Miami, Florida 33127 (hereinafter referred to as "Diamedix") and
Maria Cossi, a citizen of Italy residing at Via Stesicoro, 148-Roma and Riccardo
Cossi, a citizen of Italy residing at Via Stesicoro, 148-Roma (hereinafter
individually referred to as an "Inventor" and collectively as the "Inventors")

                                  WITNESSETH:
                                  -----------

     WHEREAS, Diamedix and the inventors entered into that certain Assignment
and Royalty Agreement, dated December 12, 1994, whereby, among other things, the
inventors assigned to Diamedix their entire exclusive right, title and interest
throughout the world in and to certain Inventions, Instruments, Technical
Information, patents and patent applications (the "Assignment and Royalty
Agreement");

     WHEREAS, Dimedix and the Inventors desire to amend the Assignment and
Royalty Agreement in accordance with the terms and conditions of this Amendment;

     NOW, THEREFORE, for and in consideration of the mutual covenants contained
herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, agree as follows:

                                    AGREEMENT
                                    ---------

     1. Unless otherwise specifically defined herein, capitalized terms used in
this Amendment shall have the Meanings ascribed to them in the Assignment and
Royalty Agreement.

     2. The Inventors have developed two versions of Instrument #1, one which
had previously been designated as EASY EIA 1 and is currently called MAGO A,
which instrument is described on Exhibit A to the Assignment and Royalty
Agreement (herein referred to MAGO A) and the other which is currently called
MAGO PLUS and is described on Exhibit A2 attached to this Amendment and made a
part hereof by this reference (herein referred to MAGO PLUS). Accordingly, the
parties agree that the definition of Instrument #1 in the Assignment and Royalty
Agreement is hereby expanded to include not only the MAGO A version but also the
MAGO PLUS version, that the attached Exhibit A2 is hereby made a part of the
Assignment and Royalty Agreement as an additional description of Instrument #1,
and that all references In the Assignment and Royalty Agreement to Instrument #
1 shall include both versions unless otherwise indicated herein.
<PAGE>

     3. The characteristics of Instrument #2 which had previously been
designated as EASY EIA 2 and is currently called MAGO B have been modified
somewhat since the date of the Assignment and Royalty Agreement and therefore
the parties agree that the Exhibit B which is attached to the Assignment and
Royalty Agreement be deleted in its entirety and replaced with the preliminary
description of MAGO B set forth on Exhibit B attached to this Amendment and made
a pact hereof by this reference. Hereinafter, any reference to the MAGO B or the
Instrument #2 In this Amendment or the Assignment and Royalty Agreement shall
have the same meaning.

     4. The Inventors hereby affirm the representation and warranties trade
under Section 2 of the Assignment and Royalty Agreement. In addition to such
representations and warranties, the Inventors further represent that the
prototype of MAGO PLUS has been developed and is ready for production, and that
the final MAGO B Instrument Specifications will be completed by August 31, 1997.

     5. Section 3.1 (1) of the Assignment and Royalty Agreement is hereby
amended to read as follows:

     "(i) $1,000 for each Instrument #1 produced by Diamedix or any of its
affiliates, provided, however, that the foregoing payment shall not be
applicable for the first fourteen Instruments # 1 produced; and"

     6. Section 3.2 of the Assignment and Roya1ty Agreement is hereby amended
such, that the royalty payments required with respect to Section 3.1 (1) will
not be due until 18 months after production of the 15th MAGO A Instrument and
the royalty payments required for the MAGO A and the MAGO PLUS Instruments under
Section 3.1 (i) shall cease to be due and payable five years after the
production of the 15th MAGO A Instrument. Accordingly, the words "the 11th
Instrument #1" on line 2 and 9 of Section 3.2 are hereby changed to "the 15th
MAGO A Instrument #1. In addition, in respect to Section 3.1 (ii), royalty
payments will not be due until 18 months after production of the 15th. MAGO B
Instrument and the royalty payments required for the MAGO B Instrument under
Section 3.1 (ii) shall cease to be due and payable five years after the
production of the 15th MAGO B Instrument. Accordingly, the words "the 11th
Instrument #2" on lines 3,4 and 10 of Section 3.2 are hereby changed to "the
15th MAGO B."

     7. Section 3.3 of the Assignment and Royalty Agreement is hereby amended by
changing the words "11th Instrument #1" on the fourth line of subsection a and b
to "the 15th Instrument #1". Section 3.3 (b) is hereby further expanded by
adding the following language at the end of Section 3.3 (b): ", provided,
however, that such lump sum payment for 3.3 (b) (ii) shall not be allowed until
18 months or more after the first MAGO B is produced, but not until at least 60
MAGO B Instruments arc produced."

     8. The parties hereby acknowledge that the plans and discussions for the
development of the MAGO PLUS Instrument caused modifications and delay in the
<PAGE>

development of MAGO B and accordingly the production timetable for Instrument #2
was not met. Diamedix hereby waives it right under Section 6 of the Assignment
and Royalty Agreement to terminate the Assignment and Royalty Agreement for
failure to meet the original time frame with respect to the production of a MAGO
B prototype. However, Diamedix reserves its rights to terminate the Assignment
and Royalty Agreement without any further obligation or liability whatsoever if
the revised time frame which is so forth in Section 4 above is not met.

     9. This Amendment shall be governed by and shall be construed, interpreted
and enforced in accordance with the laws of the State of Florida.

     10. Except as expressly provided herein all provisions of the Assignment
and Royalty Agreement shall remain in full force and effect. This Amendment
together with the Assignment and Royalty Agreement represents the entire
understanding and agreement between the parties hereto with respect to the
subject matter hereof and cannot be amended, supplemented or modified except by
an instrument in writing aligned by the parties hereto.

     11. This Amendment way be executed in any number of counterparts, each of
which will be downed to be an original, and all of which together shall be
deemed to be one and the same instrument.

     IN WITNESS WHEREOF, this Amendment has been executed by the parties to be
effective as of the day and year first written above.

DIAMEDIX CORPORATION                                    INVENTORS:

By: /s/ Giorgio D'Urso                                  By: /s/ Mario Cossi
    ------------------                                      --------------------
        Giorgio D'Urso                                          Mario Cossi
        President

                                                        By: /s/ Riccardo Cossi
                                                            --------------------
                                                                Riccardo Cossi
<PAGE>

                                   Exhibit A2

                      MAGO PLUS INSTRUMENT SPECIFICATIONS

1.   Bar code sample identification

2.   Capability to run 4 microplates simultaneously

3.   Predilution of the sample by means of a single probe

4.   Ability to dispense sample in microplates

5.   Ability to dispense reagents

6.   Ability to wash 8 wells simultaneously

7.   Ability to bring the 4 microplates to working temperature independently one
     from the other

8.   Built-in computer to run the instrument

9.   Built-in reader

10.  Automated mechanism to move microplates to the reader

11.  Software featuring

     .    Random access

     .    Ability to perform from one (1) to twelve (12) different analytes
          simultaneously on the same microplate

     .    Ability to perform from one (1) to twelve (12) different analytes
          simultaneously on four (4) microp1ates

     .    Interface with computer and reader to produce patient profiles

     .    Interface of instrutment with two most widely used main frame
          computors in the Laboratory

     .    Control system to check the instrument's main functions

     .    Ability to provide historical data base

     .    Possibility for different languages
<PAGE>

                                    Exhibit B

                  PRELIMINARY MAGO B INSTRUMENT SPECIFICATIONS

1.   Floor model with controllable wheels - self sufficient, other furnishings
     not required.

2.   No exterior components, containers or connections, with the exception of
     the power supply.

3.   Able to work in continuous flow and simultaneously accept new samples as
     well its the reagents requited to run them, compatibly with the
     instrument's maximum output. Safety measures must allow the operator to
     change or add reagents, etc. while the instrument is in operation.

4.   Must have a fixed bar code-reader for sample identification and the ability
     to count the samples and establish reagent volumes required to complete the
     run.

5.   Minimum requirements should include:

     .    Microplate reader

     .    Probe with disposable tips, automatic management of tip replacement
          and supply and at least one non polluting liquid sensor.

     .    Self cleaning probe with level sensor

     .    Microplate washing system

     .    System to coordinate automatic rearrangement of reagents as needed

     .    Appropriate sensors to assure correct functioning of each instrument
          part

     .    Safety system to avoid serious damage to the instrument in case of
          malfunction.

6.   MAGO B must be capable of handling 400 samples, 400 predilution cups, t6
     microplates 1000 tips and enough reagents to complete the run. It must
     accommodate 3 different wash solutions for a total of about 10 liters, at
     least 4 liters of distilled water and containers must hold at least 16
     liters of liquid waste.

7.   Electronic control panel and power supply will be lodged within the
     Instrument. Interface with the operator will occur through a built in
     computer, the keyboard, the monitor and the mouse will be placed on work
     shelves that are integral parts of the instrument.

8.   MAGO B will perform the following functions automatically:

     .    Accept new samples and components (tips, plates, reagents, predilution
          cups) during the course of a run.
<PAGE>

     .    Dilute samples in the appropriate dilution cups by means of a probe
          with disposable tips.

     .    Wash the probe and replace tips as needed.

     .    Transfer diluted and undiluted samples to microplates by means of a
          probe with disposable tips.

     .    Add reagents in the single wells of the plate

     .    Incubate plates at selected temperatures

     .    Wash and dry single strips of the plate

     .    Read the plate

     .    Save samples for future tests.

Note: Design will be based security and ergonomics of the user as well as on
      the appearance of the instrument. Particular attention must be given to
      making the assembly and maintenance as simple as possible.
<PAGE>

              SECOND AMENDMENT TO ASSIGNMENT AND ROYALTY AGREEMENT

     This Second Amendment to Assignment and Royalty Agreement (the "Second
Amendment") is made and entered into as of the 1st day of September, 1999
by and between Diamedix Corporation, a Florida corporation having its principal
place of business located a 2140 North Miami Avenue, Miami, Florida 33127
(hereinafter referred to as "Diamedix") and Mario Cossi, a citizen of Italy
residing at Via Stesicoro, 148-Roma and Riccardo Cossi, a citizen of Italy
residing at Via Stesicoro, 148-Roma (hereinafter individually referred to as an
"Inventor" and collectively as the "Inventors")

                                   W1TNESSETH:
                                   -----------

     WHEREAS, Diamedix and the Inventors entered into that certain Assignment
and Royalty Agreement, dated December 12, 1994, whereby, among other things, the
Inventors assigned to Diamedix their entire exclusive right, title and interest
throughout the world in and to certain Inventions, Instruments, Technical
Information, patents and patent applications (the "Assignment and Royalty
Agreement");

     WHEREAS, Diamedix and the Inventors entered into an Amendment to Assignment
and Royalty Agreement dated February 1, 1997, whereby, among other things, to
redefine certain terms and revise certain provisions (the "Amendment to
Assignment and Royalty Agreement");

     WHEREAS, the Assignment and Royalty Agreement and the Amendment to
Assignment and Royalty Agreement are hereinafter collectively referred to as the
"Assignment and Royalty Agreement"; and

     WHEREAS, Diamedix and the Inventors desire to amend the Assignment and
Royalty Agreement in accordance with the terms and conditions of this Second
Amendment;

     NOW, THEREFORE, for and in consideration of the mutual covenants contained
herein and for other good and valuable consideration, the receipt and
sufficiency of which and hereby acknowledged, the parties hereto, intending to
be legally bound, agree as follows:
<PAGE>

     1. Unless otherwise specifically defined herein, capitalized terms used in
this Second Amendment shall have the meanings ascribed to them in the Assignment
and Royalty Agreement.

     2. The foregoing recitals are true and correct and are incorporated herein
by reference.

     3. Pursuant to Section 3.2 of the Assignment and Royalty Agreement, the
various royalty payments from Diamedix to the Inventors cease to be due and
payable five years (a) after the production of the 15th MAGO Instrument #1 and
(b) after the production of the 15th MAGO B Instrument. The actual date of
production of the 15th MAGO Instrument #1 is January 25, 1996. The MAGO B
Instrument was never produced. ( collectively "Original Expiration of Royalty
Payments").

          Simultaneous to the execution of this Second Amendment, Riccardo Cossi
has executed a Termination of Consulting Agreement with Diamedix and Mario Cossi
has entered into a Consultant Agreement II with IVAX Diagnostics, Inc., the
parent company of Diamedix.

          In consideration of Riccardo Cossi executing the Termination of
Consulting Agreement and Mario Cossi entering into the Consultant Agreement II,
Diamedix hereby agrees to extend the royalty payments under Section 3.2 of the
Assignment and Royalty Agreement until August 31, 2002 ("Extension of Royalty
Payments").

     4. In the event the Consultant Agreement II is terminated by either party
prior to the time for the Original Expiration of Royalty Payments, then the
expiration of the royalty payment shall revert back to the Original Expiration
of the Royalty Payments and this Second Amendment shall become null and void and
no longer in effect and the terms and conditions for royalty payments shall be
govern by the Assignment and Royalty Agreement.

     5. Furthermore, if the Consultant Agreement II is terminated prior to the
expiration of the Extension of Royalty Payments, then the Assignment and Royalty
Agreement will terminate simultaneous therewith and there shall be no additional
royalty payments due except for those payments that accrued through the day of
termination.

     6. This Amendment shall be governed by and shall be construed, interpreted
and enforced in accordance with the laws of the State of Florida.
<PAGE>

     7. Except as expressly provided herein, all provisions of the Assignment
and Royalty Agreement shall remain in full force and effect. This Second
Amendment together with the Assignment and Royalty Agreement represents the
entire understanding and agreement between the parties hereto with respect to
the subject matter hereof and cannot be amended, supplemented or modified except
by an instrument in writing signed by the parties hereto.

     8. This Amendment may be executed in any number of counterparts, each of
which will be deemed to be an original, and all of which together shall be
deemed to be one and the same instrument,

     IN WITNESS WHEREOF, this Second Amendment has been executed by the parties
to be effective as of the day and year first written above.

DIAMEDIX CORPORATION                                    INVENTORS:

By: /s/ Giorgio D'Urso                                  By: /s/ Mario Cossi
    ------------------                                      --------------------
        Giorgio D'Urso                                          Mario Cossi
        President

August 20/99                                            By: /s/ Riccardo Cossi
                                                            --------------------
                                                                Riccardo Cossi
<PAGE>

               THIRD AMENDMENT TO ASSIGNMENT AND ROYALTY AGREEMENT

     This Third Amendment to Assignment and Royalty Agreement (the "Amendment"),
dated as of the 15th day of February, 2001 by and between Diamedix Corporation,
a Florida corporation having its principal place of business located at 2140
North Miami Avenue, Miami, Florida 33127 (hereinafter referred to as "Diamedix")
and Mario Cossi, a citizen of Italy residing at Via Stesicoro, 168-Roma and
Riccardo Cossi, a citizen of Italy residing at Via Stesicoro, 168-Roma
(hereinafter individually referred to as an "Inventor" and collectively as the
"Inventors").

                                   WITNESSTH:
                                   ----------

     WHEREAS, Diamedix and the Inventors entered into that certain Assignment
and Royalty Agreement, dated December 12, 1994, whereby, among other things, the
Inventors assigned to Diamedix their entire exclusive right, title and interest
throughout the world in and to certain Inventions, Instruments, Technical
Information, patents and patent applications (the "Assignment and Royalty
Agreement");

     WHEREAS, Diamedix and the Inventors entered into an Amendment to the
Royalty Agreement dated February l, 1997, whereby, among other things, it was
agreed to redefine certain terms and revise certain provisions (the "Amendment
to Assignment and Royalty Agreement");

     WHEREAS, Diamedix and the Inventors entered into a Second Amendment to the
"Assignment and Royalty Agreement" dated September 1, 1999, whereby, among other
things, it was agreed to redefine certain terms and revise certain provisions of
the "Amendment to Assignment and Royalty Agreement and the "Assignment and
Royalty Agreement".

     NOW, THEREFORE, for and in consideration of the mutual covenants contained
herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, agree as follows:

                                    AGREEMENT
                                    ---------

     1. Pursuant to Section 3.2 of the Assignment and Royalty Agreement, and
Section 3. of the Second Amendment to Assignment and Royalty Agreement, the
royalty payments from Diamedix to the Inventors cease to be due and payable as
of August 31, 2002 ("Extension of Royalty Payments"). The parties hereby agree
that to date, the Inventors have been paid such royalties through the calendar
quarter ended September 30, 2000, which was inclusive through Instrument #1
serial number 624. Furthermore, the parties hereby agree that future royalty
payments will be made during the third quarter following the quarter for which
royalties are being calculated. As an example, the royalties for the quarter
ending December 31, 2000 will be payable during the calendar quarter ending
September 30, 2001. Any such royalty payments will be adjusted to
<PAGE>

include the effect of any credits or returns relating to the sale of any
previous Instrument #1 for which royalty payments have been made.

     2. This Amendment may be executed in any number of counterparts, each of
which will be deemed to be an original, and all of which together shall be
deemed to be one and the same instrument.

     IN WITNESS WHEREOF, this Amendment has been executed by the parties to be
effective as of the day and year first written above.

DIAMEDIX CORPORATION                                    INVENTORS:

By: /s/ Giorgio D'Urso                                  By: /s/ Mario Cossi
    ------------------                                      --------------------
        Giorgio D'Urso                                          Mario Cossi
        President

                                                        By: /s/ Riccardo Cossi
                                                            --------------------
                                                                Riccardo Cossi<PAGE>

                                                                    EXHIBIT 10.6

                          USE OF NAME LICENSE AGREEMENT
                          -----------------------------

     THIS USE OF NAME LICENSE AGREEMENT (the "Agreement") is made March 14, 2001
("the Effective Date") by and between IVAX Diagnostics, Inc. ("Diagnostics"),
formerly known as B2BSTORES.COM INC. ("B2B"), a Delaware corporation, and IVAX
Corporation ("IVAX"), a Florida corporation.

                                    RECITALS

     WHEREAS, on November 21, 2000, IVAX Corporation and B2B entered into a
merger agreement whereby IVAX Diagnostics, Inc. a Florida corporation and wholly
owned subsidiary of IVAX, would, through a statutory merger, be merged with and
into B2B (the "Merger") and B2B was to become the surviving corporation
following the Merger;

     WHEREAS, as part of the Merger, and with the consent of IVAX, B2B changed
its name to Diagnostics and B2B is to be known as "IVAX Diagnostics, Inc."
Diagnostics desires to use the name "IVAX" in its name and in connection with
the offering of its products and services post merger and IVAX is agreeable to
allow Diagnostics to use its name in such manner;

                                   AGREEMENT

     NOW THEREFORE IN CONSIDERATION of the mutual promises, covenants and
agreements contained herein, the parties agree as follows:

     1. License. In consideration of the payment of $1 and other good and
valuable consideration the sufficiency and receipt of which are hereby
acknowledged, IVAX grants to Diagnostics a fully paid, royalty free,
non-exclusive license (the "License") to use the name "IVAX" (the "Name") and
any stylized logos or marks associated with the name (collectively, the Name,
stylized logos and marks are referred to herein as the "Licensed Property") (i)
in its name, promotional literature and product and service descriptions and
(ii) for other general commercial purposes all in accordance with the terms and
conditions set forth in this Agreement.

     2. Rights and Title to Licensed Property. Diagnostics acknowledges that,
unless and until IVAX transfers to Diagnostics all rights, title and interest in
and to all of the Licensed Property, as provided in Section 4 below, all rights,
title and interest in and to the Licensed Property shall remain with IVAX.
Unless and until such transfer occurs, other than the license granted in this
Agreement, Diagnostics disclaims any right or interest to the Licensed Property
or the good will derived therefrom.

     3. Protection of the Name. Diagnostics agrees that during the term of this
Agreement it shall use commercially reasonable efforts to protect the Licensed
Property, use the Licensed Property only in accordance with IVAX' written
instructions and prevent its unauthorized use by third parties. Diagnostics
shall promptly provide IVAX
<PAGE>

written notice of all such unauthorized uses and a written description of the
actions Diagnostics has taken or is taking to prevent such unauthorized use.
Where IVAX in the exercise of its sole discretion deems appropriate, IVAX will
permit Diagnostics to intervene in any litigation brought by or against IVAX
concerning the Licensed Property. Diagnostics agrees that it will take all
commercially reasonable actions requested by IVAX that IVAX, in good faith,
reasonably believes are necessary for the protection of the Licensed Property.
Diagnostics covenants that it will not take any actions that will damage or harm
the Licensed Property.

     4. Abandonment of Licensed Property. If IVAX decides that it no longer
wishes to the Licensed Property for any commercial purpose whatsoever, and it
determines to abandon the same, then, IVAX agrees that upon making such
determination it shall provide written notice of such determination immediately
to Diagnostics and upon payment by Diagnostics of $1, shall transfer all of
IVAX' rights, title and interest in and to the Licensed Property to Diagnostics.
IVAX and Diagnostics shall execute any and all documents necessary to effectuate
such transfer. The date that this transfer becomes effective shall be known as
the "Transfer Date."

     5. Term of Agreement. This Agreement shall commence on the Effective Date
and continue thereafter until the Transfer Date, unless earlier terminated
pursuant to Section 8 below.

     6. Sublicensing and Assignment. Diagnostics may not sublicense this License
to any third party. Neither party may assign their rights and obligations under
this Agreement to any third party without the express written consent of the
other party. Notwithstanding the foregoing Diagnostics may sublicense, and
either party may assign, this Agreement to a wholly owned subsidiary.

     7. Representations and Warranties of IVAX. IVAX represents and warrants to
Diagnostics that to its knowledge it owns the Licensed Property and has the
right to license the Licensed Property to Diagnostics. IVAX further represents
that to its knowledge its use of the Licensed Property and the License hereunder
do not infringe upon the rights of any other person and no person has made any
claim related thereto.

     8. Termination; Effect of Termination. IVAX may terminate this Agreement;
at any time after the first anniversary of the Effective Date and prior to the
Transfer Date (i) upon providing Diagnostics ninety (90) day's prior written
notice of its intent to terminate and the date upon which the Agreement shall
terminate; or (ii) upon providing Diagnostics thirty days written notice of any
breach of this Agreement by Diagnostics, which breach remains uncured at the end
of the thirty (30) day period. The parties acknowledge that upon termination of
the Agreement pursuant to this Section 8 Diagnostics will have to amend its
Certificate of Incorporation to change its name and that such action will
require the affirmative vote of its stockholders. Diagnostics agrees that it
shall take all steps as are reasonably necessary to change its name as soon as
is practicable following receipt of written notice from IVAX.

                                       2
<PAGE>

     9. Entire Agreement; No Oral Modifications. This Agreement contains the
entire agreement among the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and understandings with respect
thereto and may not be amended or modified except in a writing signed by all of
the parties hereto.

     10. Binding Effect; Benefits. This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective heirs, successors
and assigns; however, nothing in this Agreement, expressed or implied, is
intended to confer on any other than the parties hereto, or their respective
heirs, successors or assigns, any rights, remedies, obligations or liabilities
under or by reason of this Agreement.

     11. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original and all of which
together shall be deemed to be one and the same instrument.

     12. Governing Law. This Agreement shall be governed by, and construed and
enforced in accordance with the laws of the United States and the State of
Florida, both substantive and remedial. Exclusive venue and jurisdiction for any
action arising hereunder shall lie in a competent court of jurisdiction located
in Dade County, Florida, and the parties specifically agree to submit to such
jurisdiction and waive any objections to such venue.

     13. Notices. All notices, requests, demands and other communications called
for or contemplated hereunder shall be in writing and shall be deemed to have
been duly given if personally delivered against written receipt or by facsimile
transmission or mailed first class certified mail, return receipt requested, or
mailed by overnight courier prepaid to the parties at the following addresses or
facsimile numbers:

     (a)  If to IVAX to:

     4400 Biscayane Boulevard
     Miami,Florida 33137
     Attention:General Counsel
     Facsimile:(305)575-6049

     (b)If to Diaganostics

     2140 North Miami Avenue
     Miami,Florida 33137
     Attention:President and Chief Executive Officer
     Facsimile:(305)324-2395

     14. Headings. The section headings herein are included for convenience only
and are not to be deemed a part of this Agreement.

     15. Remedies. Each of the parties to this Agreement shall be entitled to
enforce its rights under this Agreement specifically to recover damages and
costs

                                       3
<PAGE>

(including reasonable attorneys' fees) for any breach of any provision of this
Agreement and to exercise all other rights existing in its favor. The parties
agree that money damages may not be an adequate remedy for either party in the
event of a breach of the material provisions of this Agreement, and that either
party may apply to any court of law or equity of competent jurisdiction for
specific performance and/or injunctive relief (without posting any bond or
deposit) in order to enforce or prevent any violations of the provisions of this
Agreement. The rights and remedies given in this Agreement to a non-defaulting
party shall be deemed cumulative, and the exercise of one of such remedies shall
not operate to bar the exercise of any other rights and remedies reserved to a
non-defaulting party under this Agreement or given to a non-defaulting party at
law or in equity.

     16. Attorneys' Fees. In the event of any dispute or controversy arising out
of this Agreement, the prevailing party shall be entitled to recover from the
other party all costs and expenses, including reasonable attorneys' fees and
accountant fees, incurred in connection with such dispute or controversy.

     17. Construction. Where specific language is used to clarify by example a
general statement contained herein, such specific language shall not be deemed
to modify, limit or restrict in any manner the construction of the general
statement to which it relates. The language used in this Agreement shall be
deemed to be the language chosen by the parties to express their mutual intent,
and no rule of strict construction shall be applied against any party.

     18. Nouns and Pronouns. Whenever the context may require, any pronouns used
shall include the corresponding masculine, feminine or neuter forms, and the
singular shall include the plural and vice versa.

                 REMAINDER OF THIS PAGE LEFT INTENTIONALY BLANK

                                       4
<PAGE>

IN WITNESS WHEREOF, the parties have executed this Agreement by their authorized
representatives effective as of the date first above written.

IVAX CORPORATION

By:/s/Carol.J.Gillespie.
   ---------------------------
Name:CAROL.J.GILLESPIE.
     -------------------------
Title:SENIOR VICE PRESIDENT.
      ------------------------

IVAX DIAGNOSTICS, INC., F/K/A B2BSTORES.COM, INC.

By: /s/Giorgio D'urso
   ---------------------------
Name: GIORGIO D'URSO
     -------------------------
Title:PRESIDENT +CEO.
      ------------------------

                   SIGNATUIRE PAGE TO NAME LICENSE AGREEMENT

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]